<DOC>
	<DOCNO>NCT01586156</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) serious condition characterize endothelial dysfunction lead pulmonary vascular constriction , smooth muscle endothelial proliferation , progressive right-sided heart failure . The severity pulmonary hypertension mostly determine response right ventricle ( RV ) increase afterload pulmonary pressure , RV failure lead cause death PAH . Most accepted therapy PAH aim vasodilation pulmonary vasculature , little thought PAH patient would benefit traditional left heart failure treatment . A cornerstone therapy leave heart failure £ ] -adrenergic receptor blockade ability reverse cardiac remodel improve clinical outcome , despite decade concern regard propensity exacerbate heart failure . It report reduce mortality 30 % patient , precise mechanism contribute beneficial effect remain elucidated , evidence patient underlie contractile reserve ( i.e. , via recruitment viable myocardium £ ] -adrenergic receptor stimulation ) may experience great recovery cardiac function . In study use rat pulmonary hypertension treat £ ] blocker , RV function improve , maladaptive myocardial remodeling prevent .</brief_summary>
	<brief_title>PAHTCH ( Carvedilol )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Men woman age 18 old great age 65 year Diagnosis pulmonary arterial hypertension class 1 , 3 , 4 , 5 ( Dana Point 2008 ) NYHA/WHO Class IIII PAH medication must initiate accord late consensus statement recommendation remain stable last 30 day Women childbearing age must use doublebarrier local contraception till completion study Subjects must demonstrate understanding study , sign informed consent , reliable method communication contact ability comply study requirement Participation treatment study enrollment Significant illness past 30 day require hospitalization Hepatic insufficiency ( transaminase level &gt; 4 fold upper limit normal bilirubin &gt; 2 fold upper limit normal ) , History HIV , Hepatitis B C Serum creatinine &gt; 2.8 mg/dl Pregnancy , breastfeeding , lack safe contraception Acute decompensated heart failure within past 30 day Known allergy intolerance carvedilol β blocker Significant , persistent bradycardia ( rest heart rate &lt; 50 bpm ) hypotension ( systolic blood pressure &lt; 100 mmHg mean blood pressure &lt; 70 mmHg ) time enrollment Second thirddegree AV block without pacemaker Use CYP2D6 isoenzyme inhibitor ( quinidine , fluoxetine , paroxetine , propafenone ) increase drug level result great vasodilating effect hypotension Use hypotensive drug deplete catecholamine ( reserpine monoamine oxidase inhibitor ) may lead great sign hypotension bradycardia Other medical psychosocial condition determine principal investigator deem unsuitable enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>